1. Academic-Industry Partnership Symposium Presented by: Blank Rome LLP

2. The mission of PhIND is to create a collaborative research organization that attracts excellent scientists, accelerates the pace of research on neurodegenerative disorders, and establishes a leading, internationally-recognized center of Neuroscience discovery and development.

3. Panel Members Todd Abrams, PhD – BioStrategy Partners
Gordon Lutz, PhD – LifeSplice Pharma, LLC
Stephen Nappi – Temple University
David Gitlin, Esq. – Blank Rome LLP
Ezra Felker – Nupathe Inc.
John Reid, PhD, MBA – AstraZeneca

4. Barriers to Collaboration
Ecosystem member
Member associated barriers
Principal Investigator/ Inventor
Not interested in performing industry focused experiments (Identified by Industry)
Not informed about IP and commercialization (identified by Industry and TTO)
PI signs agreements (identified by TTO)
No promotions for inventing (traditional barrier)
Management and urgency of data (Identified by Industry)
Technology Transfer Office
Lack of resources for IP and commercialization (TTO barrier)
Multiple offices review documents (TTO barrier)
Mismatch of expectations (traditional Industry barrier)
Patent Policy not considered legally binding by PI (PI identified)

5. Barriers to Collaboration
Ecosystem member
Member associated barriers
Legal
Research agreements aligned to one side or the other due to legal representative (traditional barrier)
Long review and over-engineered documents (general comment)
Solution Academia associated barriers
Third parties assist TTO and investigator to explain commercialization issues
Legal informs investigator IP policy is binding and no agreements outside University are permitted
Develop common agreements with compromise language
Sets expectations.
Permits focus on the commercialization plan
Reduces legal review time

6. Barriers to Collaboration
Ecosystem member
Member associated barriers
Biotech and Pharmaceutical Industry
Intellectual Property rights for improvement and related inventions (self identified, TTO and Legal)
ROI and academic expectations do not match (general barrier)
On time on budget (i.e. urgency of data) (for TTO and PI)
Solution industry barriers
Reward all innovation through planned co-development
Match investment with results
Make sure termination provisions are comprehensive

7. New Models of Collaboration
“Drug discovery on campus” one to one industry to University relationships with a new purpose
Disease focus interest groups model (PhIND, Philly Derm)
Consortium Model
Regional technology exchange (Science Center – QED)
Example models: Coulter; MaRS District, CPATH
New Barriers: New purpose of research; Complex agreements including financial, IP, operations and governance issues different from sponsored research

8. New Models of Collaboration
Key points of Discussion:
Agreements some proprietary information such as compounds and targets not shared
Shared resource opportunities
Follow on research milestone based to reward success
Avoid IP argument by company having license to IP and data related to company compounds
Provisions to rewards academic innovation
Key to success: dedicated project and alliance management

9. Q & A dfa Thank you for your support!